UPBNasdaqPharmaceutical PreparationsFiscal year ends December 31

Upstream Bio, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$2.80+0.04 (+1.45%)

Close on Oct 19, 2026

Market cap: $152.79M
P/E (TTM): –
Dividend yield: –

Upstream Bio, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	2.85	2.37	2.38
Research & Development	137	63	32
General & Administrative	26	17	11
Operating Expenses	163	80	42
Operating Income	-160	-78	-40
Interest & Investment Income	17	12	4.17
Other Non-Operating Income	17	15	20
Asset Impairment Charges	0	0	0
Income Tax Expense	0	0	0
Net Income incl. Noncontrolling Interests	-143	-63	-21
Net Income	-143	-63	-21
Preferred Dividends	–	0	0
Net Income to Common	-143	-76	-38
EPS (Basic)(per share)	-2.66	-5.58	-12.95
EPS (Diluted)(per share)	-2.66	-5.58	-12.95
Shares Outstanding (Basic, Weighted)(shares)	54	14	2.95
Shares Outstanding (Diluted, Weighted)(shares)	54	14	2.95
EBITDA	-160	-78	-40

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -5382.6%
Net margin: -4955.7%
Return on equity, FY2025: -35.4%

Financial strength

Current ratio: 27.99
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 794.9%

Valuation

P/E ratio: –
Price to sales: 48.38
Price to book: 0.56
Dividend yield: –